An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

Recruiting

Phase 1

AfimkibartAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

Sponsor:

Hoffmann-La Roche

Code:

NCT07665723

Conditions

Active Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Afimkibart

Caffeine

Warfarin

Omeprazole

Dextromethorphan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-19. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-07-23.